

**FEE TRANSMITTAL
for FY 2001
(Large Entity)**

Total Amount of Payment (\$)**110.00**

Complete if Known

Application Number 09/509,482

Filing Date September 15, 2000

First Named Inventor Linda A. Crofts

Examiner Name John D. Ulm

Group Art Unit 1646

Attorney Docket Number 1871-130

TECH CENTER 1600/2900

FEB 15 2002

RECEIVED

METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge the required fees to Deposit Account Number 02-2135 in the name of Rothwell, Figg, Ernst & Manbeck

☒ Charge any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status

2. ☐ Payment Enclosed

☐ Check

☐ Credit Card

FEE CALCULATION

1. FILING FEE

Fee Code	Fee \$	Fee Description	Fee Paid
101	740	Utility filing fee	[]
106	330	Design Filing Fee	[]
107	510	Plant Filing Fee	[]
108	740	Reissue Filing Fee	[]
114	160	Provisional Filing Fee	[]

SUBTOTAL \$

2. CLAIMS

Total Claims	Independent Claims	Multiple Dependent Claims	Extra Claims	Fee	Fee Paid
[]	[]	[]	- 20** = [] x	\$18 = []	[]
[]	[]	[]	- 3** = [] x	84 = []	[]
[]	[]	[]	+ 280 = []		[]

**or number previously paid, if greater;

SUBTOTAL \$

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Fee Code	Fee Paid	Fee Description	Fee Paid
105	130	Surcharge - late filing fee or oath	[]
127	50	Surcharge - late provisional filing fee or cover sheet	[]
139	130	Non-English specification	[]
147	2,520	For filing a request for reexamination	[]
112	920	Requesting publication of SIR prior to Examiner action	[]
113	1,840*	Requesting publication of SIR after Examiner action	[]
115	110	Extension for reply within first month	[110.00]
116	400	Extension for reply within second month	[]
117	920	Extension for reply within third month	[]
118	1,440	Extension for reply within fourth month	[]
128	1,960	Extension for reply within fifth month	[]
119	320	Notice of Appeal	[]
120	320	Filing a brief in support of an appeal	[]
121	280	Request for Oral Hearing	[]
138	1,510	Petition to institute a public use proceeding	[]
140	110	Petition to revive -unavoidable	[]
141	1,280	Petition to revive - unintentional	[]
142	1,280	Utility issue fee (or reissue)	[]
143	460	Design issue fee	[]
144	620	Plant issue fee	[]
122	130	Petitions to the Commissioner	[]
123	50	Processing fee under 37 CFR 1.17(q)	[]
126	180	Submission of Information Disclosure Statement	[]
581	40	Recording each patent assignment per property (times number of properties)	[]
146	740	Filing a submission after final rejection (37 CFR 1.129(a))	[]
149	740	For each additional invention to be examined (37 CFR 1.129(b))	[]
179	740	Request for Continued Examination (RCE)	[]
169	900	Request for expedited examination of a design application	[]
195	300	Publication fee for early, voluntary, or normal publication	[]
196	300	Publication fee for republication	[]
089	200	Filing application for patent term adjustment	[]
090	400	Request for reinstatement of term reduced	[]
		Other fee (specify)	[]


* Reduced by Basic Filing Fee Paid

SUBTOTAL

\$110.00

SUBMITTED BY		Complete (if applicable)	
NAME AND REG. NUMBER	Barbara G. Ernst, Reg. No. 30,377		
SIGNATURE	Barbara G. Ernst	DATE	Feb. 11, 2002
		DEPOSIT ACCOUNT USER ID	

#8/Election/
Amolt B
2-20-02



<p align="center">IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</p>	Application Number	09/509,482
	Filing Date	September 15, 2000
	First Named Inventor	Linda A. Crofts
	Group Art Unit	1646
	Examiner Name	John D. Ulm
	Attorney Docket Number	1871-130
<p>Title of the Invention: Isoforms of the Human Vitamin D Receptor</p>		

RECEIVED
FEB 15 2002
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated December 10, 2001, please enter the amendments summarized below.

Amend claims 1, 10 and 17 as shown on the following pages.

Marked-up copies of the original text of the amended portions of the claims are attached to this amendment. Material inserted is indicated by redlining (insertion) and material deleted is indicated by strike-out (~~strike-out~~).

Clean Copy of Amended Claims:

B₁ ~~See C4~~ Claim 1. An isolated polynucleotide molecule encoding a human Vitamin D receptor (hVDR) isoform, said polynucleotide molecule comprising a nucleotide sequence which comprises a sequence that substantially corresponds or is functionally equivalent to that of exon 1d of the human VDR gene or a sequence complementary thereto.

B₂ Claim 10 (twice amended). A host cell transformed with a polynucleotide molecule according to claim 1 or a plasmid or expression vector according to claim 9.

B₃ Claim 17 (twice amended). A non-human animal transformed with a polynucleotide molecule according to claim 1 .